Retatrutide produced 28.7% weight loss at 68 weeks in the TRIUMPH-4 Phase 3 trial, compared to Tirzepatides 22.5% at 72 weeks in SURMOUNT-1
Each approach targets a different barrier to absorption, and combining strategies can produce synergistic improvements
If a clinician determines semaglutide is appropriate, a licensed pharmacy ships it to your door anywhere in the county, and follow-ups continue by message or video
The current once-weekly subcutaneous injection model works, but once-monthly or even implantable formulations are on the horizon
The switch depends on your remaining beta cell function, current glucose control, overall health status, and treatment goals
Si tiene brazos delgados, considere usar el abdomen o muslo donde hay ms tejido subcutneo